Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Share-based Compensation (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Share-based Compensation for 10 consecutive years, with $257000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 93.23% to $257000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Dec 2025, up 99.1% year-over-year, with the annual reading at $2.2 million for FY2025, 99.1% up from the prior year.
  • Share-based Compensation for Q4 2025 was $257000.0 at Rein Therapeutics, down from $1.4 million in the prior quarter.
  • The five-year high for Share-based Compensation was $1.4 million in Q3 2025, with the low at $133000.0 in Q4 2024.
  • Average Share-based Compensation over 5 years is $443700.0, with a median of $376000.0 recorded in 2021.
  • The sharpest move saw Share-based Compensation plummeted 61.64% in 2024, then surged 184.84% in 2025.
  • Over 5 years, Share-based Compensation stood at $607000.0 in 2021, then crashed by 30.15% to $424000.0 in 2022, then tumbled by 36.32% to $270000.0 in 2023, then plummeted by 50.74% to $133000.0 in 2024, then skyrocketed by 93.23% to $257000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $257000.0, $1.4 million, and $256000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.